Segmented Structured Polypeptides for Kallikrein Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing therapeutic peptides against human Kallikrein lack specificity and affinity, leading to ineffective targeting of the enzyme, particularly in hereditary angioedema and cardiopulmonary bypass surgery.
Innovation Solution
Design and synthesis of structured polypeptides with specific consensus sequences and loop lengths, covalently bound to molecular scaffolds, which form high-affinity bonds with human Kallikrein, utilizing reactive groups like cysteine for enhanced specificity and binding efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If linear peptides are used to target human Kallikrein, then the peptide structure is simple and easy to manufacture, but the binding affinity and specificity are insufficient
Solution Approach 1:
The peptide is divided into multiple segments including a cyclic region and flexible linkers, where the cyclic portion provides binding specificity and the flexible portions allow optimal positioning. This segmentation enables both structural simplicity for manufacture and high binding affinity through the cyclic constraint.
Solution Approach 2:
The peptide incorporates flexible linker regions that act as adaptable connections between the cyclic binding domain and the molecular scaffold. These flexible portions allow the peptide to adjust its conformation to optimize binding to human Kallikrein while maintaining overall structural simplicity.
2Reliability
If cyclic peptide structures are adopted to improve binding affinity, then the interaction surface and specificity increase, but the molecular complexity and manufacturing difficulty increase
Solution Approach 1:
The cyclic peptide is designed as a segmented structure with distinct functional regions: a cyclic binding domain for high affinity, flexible linkers for conformational adaptability, and a simplified scaffold for structural support. This segmentation reduces overall molecular complexity while preserving binding affinity.
Solution Approach 2:
The peptide structure utilizes controlled cyclic constraints at specific positions rather than complete macrocyclization, changing the degree of rigidity parameterically. This allows the molecule to maintain flexibility where needed while achieving sufficient binding affinity through localized cyclic structures.
3Area of stationary object
If multiple peptide loops are tethered to a molecular scaffold to enhance binding, then the interaction surface area increases, but the device complexity and synthesis difficulty increase
Solution Approach 1:
The multicyclic peptide is segmented into multiple independent loop regions tethered to a central molecular scaffold. Each loop can be optimized for specific binding interactions while the scaffold provides a simplified structural framework, increasing interaction surface area without proportionally increasing overall complexity.
Solution Approach 2:
The molecular scaffold serves multiple functions simultaneously: it provides structural support, positions multiple peptide loops for optimal binding, and reduces the overall complexity by serving as a single anchoring point for multiple cyclic regions. This multi-functionality increases interaction surface area while controlling device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides achieve nanomolar binding constants, demonstrating improved specificity and affinity for human Kallikrein, potentially offering therapeutic applications in hereditary angioedema and cardiopulmonary bypass surgery.
Implementation Method 1
a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide
Implementation Method 2
The constructs disclosed in this document rely on —SH functionalised peptides, typically comprising cysteine residues, and heteroaromatic groups on the scaffold, typically comprising benzylic halogen substituents such as bis- or tris-bromophenylbenzene. Such groups react to form a thioether linkage between the peptide and the scaffold.
Data Source
AI summary
The invention describes peptide ligands specific for human plasma Kallikrein.